Evidence map›Paper›PMID 30552248›Full record

Trial reportBMJ open2018

Study protocol for a double-blind randomised controlled trial investigating the impact of 12 weeks supplementation with a

Margaret Murray, Aimee L Dordevic, Katherine H M Cox, Andrew Scholey, Lisa Ryan, Maxine P Bonham

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in BMJ open, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Margaret MurrayDepartment of Nutrition, Dietetics and Food, Monash University, Notting Hill, Victoria, Australia.ORCID 0000-0003-3767-6947
Aimee L DordevicDepartment of Nutrition, Dietetics and Food, Monash University, Notting Hill, Victoria, Australia.
Katherine H M CoxCentre for Human Psychopharmacology, Swinburne University of Technology, Hawthorn, Victoria, Australia.
Andrew ScholeyCentre for Human Psychopharmacology, Swinburne University of Technology, Hawthorn, Victoria, Australia.
Lisa RyanDepartment of Natural Sciences, Galway-Mayo Institute of Technology, Galway, Ireland.
Maxine P BonhamDepartment of Nutrition, Dietetics and Food, Monash University, Notting Hill, Victoria, Australia.
Monash University · AUSwinburne University of Technology · AUGalway-Mayo Institute of Technology · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHyperlipidaemia, hyperglycaemia and chronic inflammation are risk factors for chronic diseases cardiovascular disease and type 2 diabetes. Polyphenols are bioactive compounds found in marine algae with potential antihyperlipidaemic, antihyperglycaemic and anti-inflammatory effects. The modulation of these risk factors using bioactive polyphenols may represent a useful strategy for disease prevention and management; research in humans, however, remains limited. This trial aims to determine the impact of a polyphenol-rich brown seaweed extract on fasting hyperlipidaemia, hyperglycaemia and inflammation. Effects on mood and cognition will also be evaluated. METHODS AND ANALYSIS: Fifty-eight hypercholesterolaemic participants who are overweight or have obesity will be randomised to receive either a polyphenol-rich brown seaweed extract (2000 mg dose containing 600 mg polyphenols) or placebo (2000 mg rice flour) daily for 12 weeks. Fasting venous blood samples will be taken at baseline, week 6 and week 12 of the intervention to assess serum cholesterol (total, low-density lipoprotein and high-density lipoprotein) and triglyceride concentrations, plasma glucose and insulin concentrations and markers of inflammation. Mood and cognitive function will be evaluated as exploratory outcomes. Independent t-tests or equivalent will be used to determine differences between the two groups in changes from baseline to week 12. Analysis of variance will be used to assess differences between the groups across the three time points (baseline, week 6 and week 12). ETHICS AND DISSEMINATION: Ethics approval has been granted by the Monash University Human Research Ethics Committee (2017-8689-10379). Results from this trial will be disseminated through publication in peer-reviewed journals, national and international presentations, and a PhD thesis. These results are essential to inform the use of polyphenol-rich brown seaweeds as a functional food or nutritional supplement ingredients for health promotion and disease prevention and management in humans. TRIAL REGISTRATION NUMBER: ACTRN12617001039370; Pre-results.

Indexed as

FucusAdultAffectAnthropometryBlood PressureCholesterol, LDLCognitionDouble-Blind MethodFemaleHumansHypercholesterolemiaLipoproteins, HDLLipoproteins, LDLMaleMiddle AgedNeuropsychological TestsCholesterol, LDLLipoproteins, HDLLipoproteins, LDLPlant Extractscognitionglycaemiainflammationlipidspolyphenol

Identifiers

PMID30552248
PMCPMC6303689
OpenAlexW2904803966

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.